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pen access Abstract Three charge transfer complexes of azelastine as n-donor with p acceptors, dichloro-
dicyanobenzoquinone (DDQ), chloranilic acid (CA) and tetracyanoquinodimethane (TCNQ) were
prepared in acetonitrile. They yield a radical anions measured at 456, 520 and 841 nm within con-
centration ranges of 8.0–72, 40–320 and 1.6–14.4 lg mL1 with good correlation coefﬁcients
(r= 0.9996–0.9998). The molar absorptivities and association constants for the colored products
were evaluated using the Benesi–Hildebrand equation. The free energy change (DG0) and the
enthalpy of formation (DH0) as well as the entropy (DS0) were determined for the reaction product
with TCNQ. The methods were successfully applied to the analysis of azelastine in its pharmaceu-
tical preparations, where no interferences could be observed from the additives commonly present
in the eye drops or nasal spray as proved by good mean recoveries of 98.89 ± 1.06–99.54 ± 1.84%.
The results were compared, favorably with the manufacturer method and validated according to
ICH guidelines.
ª 2011 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.m (S.A. Abdel-Razeq).
Cairo University. Production
aculty of Pharmacy, Cairo
lsevier
under CC BY-NC-ND license.1. Introduction
Azelastine HCl is 4-(4-chlorobenzyl)-2-[(4RS)-1-methylhexa-
hydro-1H-azepin-4-yl]phthalazin-1(2H)-one hydrochloride1
(Fig. 1). It is an intranasal antihistamine indicated for allergic
rhinitis, conjunctivitis and vasomotor.2–4 Few analytical meth-
ods were reported for its determination including volumetry,5
UV spectrophotometry,5 colorimetry,6 TLC,7 HPLC8–10 and
capillary electrophoresis.11 The aim of the present study is to
develop a simple and rapid spectrophotometric method for
analysis of azelastine-HCl in its pharmaceutical formulations.
The association constant and standard free energy change
(DG0) are studied using Benesi–Hildebrand plot. The kinetic
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Figure 1 Chemical structure of azelastine HCl with molecular
formula C22H24ClN3O, HCl and molecular weight 418.4.
14 N.N. Salama et al.study and thermodynamic parameters of the drug with TCNQ
were also determined.
2. Experimental
2.1. Instrument
Shimadzu UV-1601 PC and Shimadzu UV–vis 160, dual-beam
spectrophotometers (Japan).
2.2. Materials and reagents
All solvents used were of spectroscopic grade and bidistilled
water was used throughout the work. Azelastine-HCl (purity
99.00%) was kindly supplied from European Egyptian Pharm
Co., Egypt. Zalastine nasal spray labeled to contain 1 mg
azelastine-HCl per mL (BN 7579001, European Egyptian
Pharm Co., Egypt) and Azelast eye drops, labeled to contain
0.5 mg azelastine-HCl per mL (BN 86872, product of El-Kah-
ira Pharm and Chem Ind Co., EPCI, Egypt) were purchased
from the local market. DDQ and CA (Aldrich–Sigma,
Germany) 0.2% (w/v) and 5 · 103 M solutions were prepared
in acetonitrile and found to be stable for 1 week in refrigerator.
TCNQ (Aldrich–Sigma, Germany) 0.1% (w/v) and 1 · 103 M
solutions, were freshly prepared in acetonitrile. Acetone, aceto-
nitrile, dioxane, ethanol, methanol (Merck Co., Germany),
chloroform (Fischer, UK), anhydrous Na2SO4, ammonia solu-
tion 33% (Adwic Co., Egypt) were also used.
2.3. Preparation of azelastine base
Accurately weighed amount of azelastine-HCl (547.79 mg)
equivalent to 500 mg of azelastine base was dissolved in
40 mL water, transferred quantitatively to 250 mL separating
funnel rendered alkaline with ammonia solution (33% w/v).
The precipitated base was extracted with 4· 20 mL CHCl3.
The combined extracts were washed with 30 mL water ﬁltered
through anhydrous Na2SO4 and evaporated to dryness. An
accurately weighed amount equivalent to about 200 or
190.95 mg of the residue was dissolved in acetonitrile and
transferred quantitatively to 100 mL volumetric ﬂask for prep-
aration of 2 mg mL1 and 5 · 103 M, respectively. The stock
solution 2 mg mL1 was used for CA method, diluted to
0.4 mg mL1 for DDQ or 0.08 mg mL1 for TCNQ usingacetonitrile. The stock solution 5 · 103 M was used for jobs
method for CA and, diluted to 1 · 103 M for DDQ and
TCNQ using acetonitrile.
2.4. Linearity
Aliquots equivalent to 0.08–0.72 mg or 0.40–3.20 mg of azelas-
tine-base standard solution (0.4 or 2 mg mL1) were trans-
ferred into two separate series of 10-mL volumetric ﬂasks.
To each series, 1.5 mL of 0.2% DDQ or 0.2% CA was added
and the volume was completed with acetonitrile. The absor-
bance was measured after about 5 min at 456 nm for DDQ
or 520 nm for CA, against the appropriate reagent blank. Plots
of absorbance against drug-base concentration were plotted
and regression equations were calculated.
For TCNQ aliquots of working drug base solution
(0.08 mg mL1) equivalent to 16.0–144.0 lg of azelastine base
were transferred into a series of stopper test tubes, followed by
1.5 mL of 0.1% of TCNQ solution and 2 mL acetonitrile. The
tubes were heated in a thermostatic water bath at 60 C for
15 min. Then cooled and the content of each tube was trans-
ferred quantitatively to a 10-mL volumetric ﬂask and com-
pleted to the mark with acetonitrile. The absorbance was
measured at 841 nm against a reagent blank treated similarly.
Absorbance was plotted against corresponding drug base con-
centrations and the regression equation was calculated.
2.5. Determination of the stoichiometry of the reaction using
Job’s method
Three series of 2 mL quantities of mixtures of equimolar solu-
tions of azelastine-DDQ, azelastine-CA and azelastine-TCNQ
were made. The ﬁrst and third series were made from
1 · 103 M of each donor and acceptor by compromising com-
plementary proportions of the two solutions (0.2:1.8,
0.4:1.6,. . .,1.8:0.2) in 10 mL volumetric ﬂasks and stoppered
test tubes for the ﬁrst and third series, respectively. The same
procedure was repeated using solutions of azelastine and CA
each of 5 · 103 M. Then the detailed procedures described
under Section 2.4 was followed. The absorbance was measured
at 456, 520 and 481 nm for DDQ, CA and TCNQ, respec-
tively, each against its appropriate blank.
2.6. Determination of association constant, molar absorptivity
and standard free energy change
Volumes of 0.2–1.0 mL of 1 · 103 M solution of azelastine
base in acetonitrile were transferred into a series of 10-mL vol-
umetric ﬂasks followed by 5 mL of 104 M of DDQ or CA in
acetonitrile. For TCNQ, aliquots of 1.0–5.0 mL of 1 · 103 M
drug base solution in acetonitrile were transferred into a series
of 10-mL stopper test tubes followed by 2 mL of 104 M
TCNQ solution. The detailed procedure under Section 2.4
was then followed for each method.
2.7. Determination of thermodynamic parameters of azelastine-
TCNQ complex
Into a series of 10 mL glass stoppered test tubes, aliquots of
drug base solution (0.08 mg mL1) equivalent to 80 lg of
azelastine base were transferred, followed by 1.5 mL of 0.1%
TCNQ and 2 mL of acetonitrile. The tubes were heated in a
Spectrophotometric determination and thermodynamic studies of the charge transfer complexes of azelastine-HCl 15thermostatic water bath at different temperatures (40, 50,
60 C) for different time intervals. At the speciﬁed time, the
tubes were cooled and the content of each tube was transferred
quantitatively to a 10 mL volumetric ﬂask, then the detailed
procedure under Section 2.4 was followed.
2.8. Application to pharmaceutical formulations
The detailed procedure under Section 2.3 were followed using
accurately measured volumes of the mixed Zalastine nasal
spray or Azelast eye drops solution equivalent to 20 mg of
azelastine base to obtain a stock solution labeled to contain
2 mg mL1, then the recommended procedures described un-
der Section 2.4 were followed.
3. Results
The absorption spectrum of azelastine base in acetonitrile was
shown in Fig. 2. The interaction of azelastine base with the p
acceptors DDQ, CA and TCNQ yield charge transfer com-
plexes which dissociate into intensity colored radical anions
in the polar solvent using acetonitrile.12–15 The maximumWavelength(nm)
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Figure 2 Zero order absorption spectra of azelastine base
(40 lg mL1), azelastine with DDQ (40 lg mL1), CA
(200 lg mL1) and TCNQ (8 lg mL1).
Table 1 Spectral and validation data for the reaction of azelastine
Parameters DDQ
kmax (nm) 456
Linearity (lg mL1) 8–72
Accuracy (mean ± RSD%) n= 6 100.50 ± 0.60
Precision (RSD) n= 15
Repeatability 0.958
Intermediate precision 0.847
Regression parameters
Slope ± SD 0.0112 ± 8.2 · 105
Intercept ± SD 0.0034 ± 1.3 · 104
SD of residual (Sxy) 9.2 · 103
Correlation coeﬃcient (r) 0.9998absorbance was measured at 456, 520 and 841 nm, respectively
(Fig. 2).
3.1. Optimization of the reaction conditions
3.1.1. Effect of reagent volume
Different volumes of 0.2% DDQ, 0.2% CA and 0.1% TCNQ
were studied. Highest absorbance at the relevant maxima was
obtained upon using 0.4–2.0 mL from each of the above chro-
mogens, hence 1.5 mL of each was used.
3.1.2. Effect of time and temperature
Complete color development was attained instantaneously at
room temperature between the drug base and DDQ or CA
and remained stable for further 1 h with DDQ or 2 h with CA.
However, with the TCNQ the reaction was slow over a per-
iod of 2 h at room temperature, suggesting heating at different
temperatures (40–60 C). The highest color intensity was at-
tained after heating at 60 C for 10 min and remained stable
for further 50 min.
3.1.3. Effect of solvents
Different solvents were tried for the reaction where the use of
acetonitrile yielded maximum color intensity.
3.2. Stoichiometry of the reaction
A molar ratio of 1:1 between drug and each of the three accep-
tors was obtained by applying Job’s method16 using equimolar
solution of the drug and each reagent.
3.3. Method validation17
3.3.1. Linearity and sensitivity
Beer’s plots were found to be linear with very small intercepts
and good correlation coefﬁcients (0.9999–0.9998) in the con-
centration range of 8–72, 40–320, and 1.6–14.4 lg mL1
azelastine base with DDQ, CA and TCNQ, respectively
(Table 1).
3.3.2. Accuracy and precision
The mean accuracies ranged between 100.2% and 100.5%. The
intraday precision was assessed by analyzing ﬁve concentra-
tions in triplicates where RSD obtained were 0.414–0.958%,
while intermediate precision was assessed by analyzing thebase with DDQ, CA and TCNQ.
CA TCNQ
520 841
40–320 1.6–14.4
100.20 ± 0.39 100.50 ± 1.15
0.414 0.655
0.428 0.497
0.0029 ± 2.2 · 104 0.0628 ± 8.17 · 105
0.011 ± 1.3x104 0.0014 ± 9.7 · 103
5.3 · 103 8.3 · 103
0.9998 0.9996
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16 N.N. Salama et al.same concentrations in three consecutive days and RSD ob-
tained were 0.428–0.847% (Table 1).
3.3.3. Ruggedness and robustness
The ruggedness was assessed by applying the proposed
procedures using two different instruments in two different
laboratories at different elapsed time. Results obtained from
lab-to-lab and day-to-day variations were found to be repro-
ducible as RSD did not exceed 2%. Robustness was assessed
by evaluating the inﬂuence of small variation of concentration
of acceptor reagent and reaction time. The small variations did
not signiﬁcantly affect the results. The mean recoveries were
100.2 ± 0.39–100.5 ± 1.15%.
3.4. Application to pharmaceutical formulations
The proposed methods were applied for the determination of
azelastine in its nasal spray and eye drops where, good recov-
eries of 98.89 ± 1.06% and 99.54 ± 1.84% were obtained,
respectively. These results were statistically compared with
those obtained by a manufacturer method,18 proving no signif-
icance difference with respect to accuracy and precision
(Table 2). The validity of the proposed methods was further as-
sessed by applying the standard addition technique (Table 2).
3.5. Association constants and standard free energy
The association constants were calculated for the interaction of
azelastine base with either DDQ, CA and TCNQ using the fol-
lowing Benesi–Hildebrand equation19 which depends on pres-
ence of one of the reacting species in large excess, so that its
concentration is virtually unaltered on formation of the
complex.
½A0
AAD
¼ 1
eAD
þ 1
eADKADC
 1½D0 ð1Þ
where [A0] and [D0] are the total concentrations of the interact-
ing species (acceptor and donor, respectively), AAD is the
absorbance of the complex, eAD is the molar absorptivity of
the complex and KADC is the association constant of the
complex.103 (1/[Do] ) Mol-1L
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Figure 3 Benesi–Hildebrand plot for DDQ, CA and TCNQ
complexes with azelastine base.
Table 3 Association constant, molar absorptivity values and
calculated free energy from Benesi–Hildebrand plots for the
complexes formed.
Parameters DDQ CA TCNQ
KADC (L mol
1) 5.1 · 103 3.1 · 104 2.6 · 103
eADk (L mol
1 cm1) 5 · 103 1.4 · 103 2.56 · 104
DG0 (kcal mol1) 5.089 6.6169 4.930
Table 5 Kinetic parameters for the reactions of azelastine
with TCNQ at different temperatures using Eyring equation.
T (K) DS* (J mol1 K1) DH* (kJ mol1) DG* (kJ mol1)
313 48.916
323 49.87
333 96.36 18.755 50.842
Spectrophotometric determination and thermodynamic studies of the charge transfer complexes of azelastine-HCl 17On plotting the values of [A0]/A
AD versus 1/[D0] straight
line was obtained (Fig. 3) whose intercept was calculated to
be 2 · 104, 7.12 · 103 or 3.9 · 105 for drug-base complex
with DDQ, CA or TCNQ, respectively, from which the corre-
sponding eAD indicated in Table 3 was calculated. The slope
was 3.9 · 108, 2.3 · 108 or 1.5 · 108 which was used to cal-
culate KADC as 5.1 · 10
3, 3.1 · 104 or 2.6 · 103 (L mol1) for the
above mentioned complexes, respectively (Table 3).
The standard free energy change of complexation (DG0) is
related to the association constant by the following equation20:
DG0 ¼ 2:303RT logKADC
where R is the gas constant (1.987 cal mol1 deg1) and T is
the temperature in Kelvin and DG0 were calculated to be
5.089, 6.6169 or 4.930 kcal mol1, respectively, as pre-
sented in Table 3.
3.6. Kinetic and thermodynamic parameters
The kinetic studies of the reaction of azelastine base with
TCNQ were carried out at different temperatures (40 C,Time, min.
2 3 4 5 6 7 8
ln
 A
i-A
t/A
i-A
0
-1.6
-1.4
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-1.0
-0.8
-0.6
-0.4
-0.2
0.0
60 oC
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40 oC
Figure 4 Pseudo ﬁrst order plots for the reaction product of
8.0 lg mL1 azelastine base with 0.1% w/v TCNQ at kmax 841 nm.
Table 4 Rate constant and half-life times of the studied
reactions of azelastine base with TCNQ at different tempera-
tures using Arrhenius plot.
T (K) k (min1) Intercept t1/2 (min) R
313 0.100 0.1589 6.93 0.9990
323 0.129 0.0518 5.37 0.9997
333 0.166 0.3825 4.17 0.999850 C, and 60 C). The plot of ln{(Ai  At)/(Ai  A0)} as a
function of time produced straight line with slope equal to
k. The equation that gave the best ﬁt for the experimental
data corresponding to ﬁrst order21 (Fig. 4) and the slope rep-
resents the rate constant. Table 4 summaries the calculated k
and t1/2 at different temperatures, from which it is evident that
as the temperature increases, the t1/2 decreases i.e. the reaction
was less time consuming.
The relationship between the reaction rate and temperature
is determined by the Arrhenius equation:
k ¼ AeEa=RT ! ln k ¼ Ea=RTþ lnA
Ea is the activation energy, R= 8.314 J mol
1, T is the abso-
lute temperature in Kelvins, and A is frequency factor.22
Linear Arrhenius curve was obtained by plotting lnk versus
1/T, and Ea was calculated from the slope to be
21.53 kJ mol1, indicating that the reactions need low activa-
tion energy, and lnA calculated from the intercept to be
5.97. The other activation parameters such as enthalpy, entro-
py and free energy of activation were calculated using Eyring
equation23,24 which was applied in the following form:
ln k=T ¼ ðDH=RÞð1=TÞ þ ln kB=hþ DS=R
where kB is Boltzmann’s constant [1.381 · 1023 J K1], h is
Plank’s constant [6.626 · 1034 J s] and ln kB/h equals 10.76,
DH* (kJ mol1) is activation enthalpy, while DS*
(J mol1 K1) is activation entropy and DG* (kJ mol1) is
the free activation enthalpy (Gibb’s free energy).
The Eyring plot of ln(k/T) versus 1/T produced a straight
line, its slope = DH*/R from which DH* was calculated to
be 18.755 kJ mol1 and DS* was calculated to be
96.36 J mol1 K1 (Table 5). The DG* (kJ mol1) which is
the free activation enthalpy was calculated from the equation
DG* = DH*  TDS*, to be 50.84 kJ mol1. The negative values
of DS* at test reduce the freedom of motion in the transition
state and relatively slow reaction that can be followed spectro-
photometrically. The positive values of DG* indicate that the
reaction of drug base with TCNQ is non-spontaneous.
4. Discussion
The absorption spectrum of azelastine base exhibits strong
band at 296 nm. The interaction of azelastine base with the p
acceptors DDQ, CA and TCNQ yield charge transfer com-
plexes which dissociate into intensity colored radical anions
in acetonitrile (polar solvent) with maximum absorbance at
456, 520 and 841 nm, respectively. All factors affecting the
reaction conditions were optimized. Acetonitrile was selected
as the best solvent, which afford maximum color intensity this
may be attributed to its high dielectric constant that promotes
maximum yield of radical anions, and its high solvating power
for p acceptors.
18 N.N. Salama et al.Stoichiometry of the reaction revealed a molar ratio of 1:1
between drug and each of the three acceptors by applying Job’s
method. This indicates that only one site is responsible for the
formation of the complex and a univalent charged species and
is the possible site of the charge transfer process, according to
the following equation:
Dþ A! ðD AÞ
Complex
! Dþ þ A
Radical ionsðin polar solventÞ
The methods were validated according to ICH guidelines,
with respect to linearity, sensitivity, accuracy, precision, rug-
gedness and robustness. The results were found to be robust
and reproducible as RSD did not exceed 2%.
The proposed methods were applied for the determination
of azelastine in its nasal spray and eye drops. These results
were statistically compared with those obtained by the manu-
facturer method proving no signiﬁcance difference with respect
to accuracy and precision. The accuracy was further assessed
by applying the standard addition technique.
The association constants were calculated for the interac-
tion of azelastine base with either DDQ, CA and TCNQ using
Benesi–Hildebrand equation which depends on presence of
one of the reacting species in large excess, so that its concentra-
tion is virtually unaltered on formation of the complex.
On plotting the values of [A0]/A
AD versus 1/[D0] a straight
lines were (Fig. 3) obtained whose intercept was corresponding
to eAD. The calculated values reveal the order of sensitivity as
follow TCNQ>DDQ> CA. The slope was used to calculate
KADC which indicates the stability of complexes and the order
was CA> DDQ> TCNQ. The standard free energy change
of complexation (DG0) is related to the association constant
and the stability of complexes.
The relationship between the reaction rate and temperature
is determined by the Arrhenius equation. Linear Arrhenius
curve indicates that the reactions need low activation energy.
The other activation parameters such as enthalpy, entropy
and free energy of activation were also calculated using Eyring
equation. The Eyring plot produced a straight line, from which
DH*, DS* and DG* were calculated. The negative values of DS*
attest reduce the freedom of motion in the transition state and
relatively slow reaction that can be followed spectrophotomet-
rically. The positive values of DG* indicate that the reaction of
drug base with TCNQ is non-spontaneous.
5. Conclusion
The proposed charge transfer complexation methods are rapid
and simple. They permit the determination of azelastine in
drug substance and pharmaceutical formulations. They com-plied with the validation scheme of the ICH and can therefore
be used for quality control and routine analysis. In addition,
thermodynamic studies were carried out on the three com-
plexes of the drug with DDQ, CA and TCNQ. The kinetic
study of the reaction with TCNQ revealed pseudo-ﬁrst order
reaction.
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